Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast 2016-2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 4, 2018--The “Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2027 report provides an overview of the disease pathogenesis, Biomarkers, various diagnostic approaches and treatment algorithm including detailed chapters for marketed products and various marketed products patent details. The report also includes in depth research related to Phototherapies for Psoriasis for the 7MM including United States, EU-5 (Germany, France, Italy, Spain and UK) and Rest of the world for the study period undertaken from 2015-2027.
Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal differentiation and hyperproliferation which affects 2-3% of the world’s population. The pathophysiology of the disease includes mainly the activation and migration of T-cells to the dermis triggering the release of cytokines (tumor necrosis factor-alpha, TNF-alpha in particular) which lead to the inflammation and the rapid production of skin cells. A number of factors are responsible for triggering psoriasis.
Among factors known to induce or worsen psoriasis are: mild localized trauma, such as scratching, piercings, tattoos, sunburns, chemical irritant, drugs including beta-blockers, lithium, anti-malarials, and non-steroidal anti-inflammatory drugs, HIV infection, and Stereptococcal pharyngitis. The climate in general and exposure to natural sun light in particular act as additional extrinsic factors with clinically important impacts on disease activity. Another factor of central importance is genetics.
Some of the key findings include:The prevalent cases of Psoriasis in the adult population in 7MM was reported to be 35,396 in 2016 The prevalence of Psoriasis in 2016 was highest in the United States, followed by the United Kingdom As per the estimates of the researcher, the prevalence of Psoriasis is expected to reach up to 4809 cases in 2020 in Italy In 2016, the prevalent population of Psoriasis was 10,627 cases in the United Kingdom
Key Topics Covered:
1 Key Insights
2 Rosacea: Market Overview at a Glance
4 Disease Background and Overview: Psoriasis
6 Epidemiology and Patient Population
7 Total Prevalent Patient Population of Psoriasis in the US & EU5
8 Total Treatable Patient Population of Psoriasis by Phototherapies in the US and EU5
9 Country Wise-Epidemiology of Psoriasis
11 Treatment Algorithm
13 Current Scenario & Future Scope
14 Unmet Needs
15 Phototherapy for Psoriasis: 7 Major Market Analysis
16 The United States Market Outlook
17 EU5 Market Outlook
18 France Market Size
19 Italy Market Size
20 Spain Market Size
21 United Kingdom Market Size
21 RoW Market Outlook
22 Market Driver
23 Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kmdx64/phototherapies?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005350/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Psoriasis Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/04/2018 07:43 AM/DISC: 10/04/2018 07:43 AM